Ticker brief
ALNY ALNYLAM PHARMACEUTICALS INC
Consumer, Non-cyclical · Biotechnology
last close
$237.10
1 day
+0.2%
14 days
+3.7%
mkt cap
$41.8B
signals 14d
23
authors 14d
11
crowd 14d
-0.7σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 44% mid · 51 pctile own 1y | IV/HV 0.52× |
| Skew — 25Δ RR 30d | -0.016 80 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.43 elevated | 5-session Δ +0.16 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2025-10-10 (z=3.7) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now -0.21 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @harry03994688 | A | -0.79 | 8 | +0.59 |
| @adamfeuerstein | A | +1.41 | 4 | -0.45 |
| @semodough | C | -3.01 | 2 | -0.12 |
| @Markadiusz45 | C | +1.18 | 2 | +0.20 |
| @AktienTrader1 | C | -0.14 | 1 | +0.35 |
| @BullTheoryio | C | -1.57 | 1 | -0.43 |
| @bioinvestor24 | A | -0.45 | 1 | -0.15 |
| @SpartanTrading | C | -1.46 | 1 | +0.00 |
| @PersimmonTI | A | -0.57 | 1 | -0.75 |
| @newsinvesting | C | · | 1 | +0.30 |
| @fwpharma | B | +0.98 | 1 | -0.15 |
Recent signals23of 23 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @fwpharma | -0.15 | Reports an AstraZeneca ATTR-CM study miss that raises questions for competing therapies. | — | tweet ↗ |
| 2026-08-28 | @newsinvesting | +0.30 | Reports ALNY falling on a rival trial while analysts view its core business as protected. | — | tweet ↗ |
| 2026-08-28 | @harry03994688 | +0.50 | ESC 2026 heart-failure guidelines reportedly add Alnylam's vutrisiran as a class-I recommendation. | — | tweet ↗ |
| 2026-08-28 | @adamfeuerstein | -0.65 | Reports adverse CARDIO-TTRansform combination-arm data and negative interpretations from three sell-side analysts. | — | tweet ↗ |
| 2026-08-28 | @PersimmonTI | -0.75 | Argues stabilizer differences make ALNY's AMVUTTRA and next-generation silencer outlook worse. | — | tweet ↗ |
| 2026-08-28 | @semodough | -0.25 | Cites Wells Fargo's view that CARDIO-TTRansform data may require modification of ALNY's TRITON trial. | — | tweet ↗ |
| 2026-08-28 | @adamfeuerstein | -0.35 | Provides subgroup cardiovascular event-rate ratios from a study relevant to four amyloidosis drug companies. | — | tweet ↗ |
| 2026-08-28 | @adamfeuerstein | -0.35 | Reports a failed AstraZeneca heart-disease study and broader concerns for silencer drugs. | — | tweet ↗ |
| 2026-08-27 | @harry03994688 | +0.50 | Advocates rotating from priced-in hardware toward software and AI-enabled biotechnology. | +0.2% | tweet ↗ |
| 2026-08-27 | @adamfeuerstein | -0.45 | Highlights adverse read-through for Alnylam from a failed heart-drug study. | +0.2% | tweet ↗ |
| 2026-08-27 | @harry03994688 | +0.75 | Author says ALNY's technology leads competitors by roughly 10x and appears substantially undervalued. | +0.2% | tweet ↗ |
| 2026-08-26 | @harry03994688 | +0.75 | Calls ALNY the top mid-cap biotech with strong expansion and clinical success potential. | -0.8% | tweet ↗ |
| 2026-08-26 | @harry03994688 | +0.60 | Author compares biotech platforms and argues ABCL could join REGN and ALNY above a 50% approval-success potential. | -0.8% | tweet ↗ |
| 2026-08-25 | @harry03994688 | +0.35 | Author expresses enthusiasm for digital biology and directs readers to research ABCL and ALNY. | -1.2% | tweet ↗ |
| 2026-08-25 | @harry03994688 | +0.75 | Author is explicitly bullish only on ALNY due to claimed clinical-test improvements. | -1.2% | tweet ↗ |
| 2026-08-25 | @harry03994688 | +0.50 | The author contrasts RNA-silencing and mRNA platforms and outlines their distinct long-term therapeutic markets. | -1.2% | tweet ↗ |
| 2026-08-24 | @SpartanTrading | +0.00 | Lists four chart ideas on watch for tomorrow without entry intent. | +0.5% | tweet ↗ |
| 2026-08-19 | @Markadiusz45 | +0.15 | Lists neglected RNA-related charts generated by ChatGPT. | -2.3% | tweet ↗ |
| 2026-08-19 | @Markadiusz45 | +0.25 | Suggests an emerging RNA-stock season and supplies a multi-name thematic basket. | -2.3% | tweet ↗ |
| 2026-08-16 | @bioinvestor24 | -0.15 | Questions KYMR's valuation, differentiation and development timeline while comparing peers and FOMO. | +3.7% | tweet ↗ |
| 2026-08-16 | @semodough | +0.00 | Reports a KOL's TTR-CM patient mix, prevalence, diagnostic trends and 20% annual practice growth. | +3.7% | tweet ↗ |
| 2026-08-16 | @BullTheoryio | -0.43 | Ranks the six worst Nasdaq 100 returns in 2026, each with losses. | +3.7% | tweet ↗ |
| 2026-08-15 | @AktienTrader1 | +0.35 | Suggests ALNY may have bottomed and notes profitability despite a 39 P/E. | +3.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.